Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 14fludarabine phosphate 9Bortezomib 9Brentuximab Vedotin 7Filgrastim 6Vorinostat 5Doxorubicin 5tanespimycin 4Whole-Body Irradiation 4Vincristine 4Peripheral Blood Stem Cell Transplantation 4Paclitaxel 4Gemcitabine 4Cyclosporine 4Cord Blood Stem Cell Transplantation 4Carboplatin 4Biopsy 4sargramostim 3romidepsin 3fludarabine 3Topotecan 3Rifampin 3Prednisone 3Mycophenolic Acid 3Magnetic Resonance Spectroscopy 3Leucovorin 3Lenalidomide 3Irinotecan 3Fluorouracil 3Everolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Large-Cell, Anaplastic × Abatacept × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡